English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Washington Just Backed Psychedelics: What the FDA and VA Announcements Mean for You
Something unusual happened in Washington recently. In the space of a single afternoon, five federal agencies — the FDA, the VA, ARPA-H, NIDA, and HRSA — all lined up publicly behind psychedelics. Not with cautious footnotes buried in a report. With actual guidance, actual funding, actual signed agreements. If you've been quietly tracking the slow federal thaw around ayahuasca, psilocybin, ibogaine, and other master plants, this was the day the thermostat jumped a few degrees. For readers weighing a psychedelic retreat, considering plant medicine for addiction, or wondering whether legal access is ever going to catch up with the science — it's worth understanding what actually got announced, and what it doesn't yet mean. The Food and Drug Administration released its final guidance for clinical investigations of psychedelic drugs. That sounds procedural, and it is. But it's the kind of procedural document pharmaceutical developers have been waiting on for years. It tells sponsors, in writing, how the agency wants trials designed — how to handle blinding when the drug is obviously not a sugar pill, how to think about the therapist's role, how to structure safety monitoring for a compound that reliably produces altered states. Final guidance isn't law. It's the FDA showing its hand. And that matters, because until now, companies developing psychedelic therapies were essentially guessing at what the agency wanted. Now they know. The FDA also announced a public hearing this autumn on the future therapeutic use of psychedelic drugs, plus an open request for public comments. Anyone can weigh in — clinicians, researchers, patients, people who've sat in ceremony. The agency even set up a dedicated psychedelics page on its website, which is a small but telling sign. When a federal regulator gives a topic its own URL, that topic isn't going away. Here's where it gets more concrete. The Department of Health and Human Services and the Department of Veterans Affairs signed a five-year Memorandum of Understanding to work together on research, clinical development, and — assuming FDA approvals come through — actual deployment of rapid-acting psychedelic treatments for veterans struggling with serious mental health conditions. Read that again. The VA is preparing to give veterans psychedelic medicine, pending approvals. This is the largest integrated healthcare system in the country, treating some of the highest rates of PTSD, depression, and suicidality in the population. The MOU commits both departments to increasing trial participation, training clinicians ahead of approvals, gathering real-world safety and cost data, and building clinical guidance for the providers who'll eventually be prescribing this stuff. A second MOU — this one between the FDA and the VA directly — expands information-sharing between the two agencies. In practice, it means the regulator and the country's biggest government healthcare provider are talking to each other about how to bring these therapies through the pipeline without the usual bureaucratic friction. For readers who care about addiction recovery, this is the headline. Ibogaine — the West African plant medicine long used in underground and offshore clinics for opioid dependence — is now being seriously funded by two separate federal agencies. The National Institute on Drug Abuse revived and validated data from earlier ibogaine studies, shared it with the FDA and outside researchers, and awarded funding to a multi-phase research project aimed at securing Investigational New Drug clearance. If that clearance lands, it would open the door to the first legal ibogaine trials on U.S. soil. NIDA is specifically interested in whether updated dosing protocols can preserve the drug's therapeutic punch while managing its well-known cardiac risks. Meanwhile, ARPA-H — the newer, DARPA-styled health research agency — put out a competitive funding opportunity for companies and academics to study ibogaine for opioid use disorder. The stated goal includes preparing for FDA review and, crucially, keeping any eventual treatment affordable and accessible. That second half matters. One of the ongoing worries about psychedelic-assisted therapy is that it becomes a boutique treatment only available to people who can drop five figures on a retreat or private clinic. Because the anecdotal and small-study evidence for ibogaine as an interrupter of opioid dependence is genuinely remarkable, and the opioid crisis is genuinely catastrophic. Federal agencies don't move fast, but they do sometimes move when the math becomes impossible to ignore. Tens of thousands of Americans are dying of overdoses every year, and standard treatments have limits. Ibogaine — for all its risks — keeps showing up in the data as something that might actually break the cycle for some people. For anyone currently researching an ibogaine retreat abroad because there's no legal option at home, the federal thaw doesn't change your options tomorrow. But it might change them in a handful of years. The Health Resources and Services Administration announced it's issuing a request for information on how the American healthcare system should prepare for a possible rollout of psychedelic therapies. The RFI is asking for input on three specific things: That third point is the one to watch. If psychedelic therapy only ever exists inside a handful of university hospitals, it stays a niche intervention for people with resources and connections. HRSA's whole mandate is community health infrastructure — federally qualified health centers, rural clinics, underserved populations. The agency is quietly asking how you make psychedelic-assisted care work at that level. Let's be honest about what today's news does and doesn't do. It doesn't legalize ayahuasca in the United States. It doesn't make psilocybin available at your local clinic. It doesn't mean you can walk into a VA hospital next month and ask for ibogaine. Legal domestic access to plant medicines remains — for most people, in most contexts — years away. What it does do is confirm that the direction of travel is real. The federal government is preparing infrastructure, funding research, and setting regulatory expectations for a future where psychedelic-assisted therapy is part of American medicine. That future is not guaranteed, and the timeline is not fast. But it's no longer speculative. For readers actively weighing a retreat right now, the practical implications are worth thinking through: The federal announcements don't shortcut any of that. They do suggest that the cultural stigma many readers still worry about — telling their doctor, their family, their employer that they're exploring plant medicine — is fading faster than it looks. The federal machinery is moving on synthesized psilocybin, MDMA, ibogaine, and other compounds that fit neatly into the drug-approval pipeline. Ayahuasca, San Pedro, peyote, and the broader tradition of master plants sit in a more complicated legal and cultural space — they're not single molecules, they're relationships with living plants embedded in indigenous ceremonial contexts. Federal approval of, say, ibogaine as a treatment for opioid use disorder doesn't automatically translate to legal ayahuasca ceremonies at your local wellness center. The traditions matter. The container matters. And a lot of what makes plant medicine work — the ceremony, the community, the songs, the facilitator's lineage — is not something the FDA has a category for. Still, the direction is clear. Psychedelic healing is being taken seriously by the institutions that decide what counts as medicine in this country. Whether you experience that as reassuring or as a warning sign about medicalization probably depends on what drew you to plant medicine in the first place. If any of this is landing for you — if you're the person quietly researching whether a retreat might help with addiction, depression, or a life pattern that won't budge — the next step is usually smaller than it feels. A range of curated ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Read carefully, ask the hard questions, and take your time. The federal government is finally catching up. You don't have to rush to meet it.
FDA Finalizes Psychedelics Guidance: What It Means for Patients and Retreat-Seekers
After nearly three years of quiet, the FDA has finally done the thing everyone in the psychedelics world was waiting on. The final guidance for clinical investigations of psychedelic drugs dropped this month, closing a chapter that opened back in June 2023 when the agency released its first draft. For anyone paying attention to psychedelic therapy — patients, clinicians, researchers, and yes, people quietly weighing whether to book an ayahuasca or psilocybin retreat — this matters more than it might look on paper. Here's the short version: the FDA has clarified how sponsors should design trials for substances like psilocybin, MDMA, LSD, DMT, and mescaline. And alongside that release, the agency and the Department of Health and Human Services announced a public hearing scheduled for September on the future of psychedelic therapies. That second announcement might end up being the more consequential news. Let's unpack what changed, what stayed the same, and — more importantly for the retreat-curious reader — what any of this actually means when you're sitting at your kitchen table trying to decide whether plant medicine is a reasonable path for you. Regulatory documents are boring on purpose. But this one shapes the entire pipeline of psychedelic medicine that's slowly moving toward FDA approval. When Compass Pathways, Lykos (formerly MAPS PBC), Cybin, and a growing bench of smaller sponsors design their trials, they lean on documents exactly like this one. The rules the FDA lays out here influence which conditions get studied, how safety is tracked, what counts as a legitimate outcome, and how long researchers have to follow patients after a dosing session. Why should you care as someone considering a retreat? Because everything happening at the clinical level eventually shapes the broader conversation around psychedelics — insurance coverage, physician attitudes, legal access, and the credibility of practitioners you might one day sit across from. When a psychiatrist eventually tells your neighbor that psilocybin-assisted therapy is a real option for their depression, that conversation traces back to documents like this one. The final guidance keeps most of the 2023 draft intact but adds meaningful clarifications on trial population selection, safety monitoring both during and after approval, and long-term follow-up design. In plain English: the FDA is taking the durability question seriously. How long do the effects actually last? What happens six months out? Twelve? These aren't rhetorical questions — they're now baked into how trials must be built. Reading the two documents side by side, a few shifts stand out. The draft was eleven pages of high-level pointers. The final version is denser, more specific, and reflects real engagement with the public comments the agency received back in the summer of 2023. Some of the more notable shifts: The guidance still doesn't solve every hard problem. Nothing solves the blinding problem — it's structural. But the final version reads like a document written by people who spent three years actually listening rather than checking a box. Buried in the same announcement is what might be the more interesting development. The FDA and HHS are convening a public hearing in September specifically on the future of psychedelic therapies, with an open request for comment. Public hearings sound sleepy until you realize what they signal. The agency is inviting testimony from clinicians, researchers, patients, veterans' groups, indigenous representatives, and industry — a broad tent. This is the kind of forum where policy pivots begin. Given the April executive order that pushed the psychedelics conversation onto the federal agenda, the September hearing looks less like a formality and more like a genuine attempt to figure out what regulatory framework these medicines deserve going forward. If you've ever wanted to submit written input as a citizen — a patient story, a caution, a request — this is a legitimate window. Public comments do get read, and in aggregate they shape how agencies frame their next moves. Here's where the regulatory world and the retreat world quietly touch. Most people looking into ayahuasca, psilocybin, or ibogaine retreats aren't waiting for FDA approval — they're dealing with depression, PTSD, addiction, or a stuck life pattern that hasn't budged despite therapy and pharmaceuticals. Fair enough. The clinical timeline is glacial compared to human suffering. But the FDA's evolving posture affects retreat-seekers in three practical ways: The catch, of course, is that FDA approval — when it comes — will apply to specific compounds in specific clinical settings for specific diagnoses. It won't legalize your ayahuasca weekend in Peru. Retreat access and clinical access are two different roads that occasionally glance at each other. If you're actively researching a retreat, use the direction of the science as a filter. A few things I'd look for right now, and would look for even more once the September hearing plays out: None of this guarantees a good experience. Plant medicine is not a product you buy off a shelf. But these markers separate the operators who take the work seriously from the ones who noticed the market got hot. The next twelve months are going to be busy. Compass has Phase 3 data on psilocybin for treatment-resistant depression and is aiming at a 2027 launch. Other sponsors are moving through their own pipelines. The September hearing will generate its own news cycle. State-level reforms — Oregon, Colorado, and whatever comes next — continue in parallel. For someone considering plant medicine as a personal path, the meta-story is this: the world of psychedelic healing is getting more organized, more scrutinized, and, slowly, more accountable. That's mostly good. It doesn't mean waiting for the FDA is your only option — but it does mean the retreat you book in 2026 should reflect the standards that the broader field is moving toward, not the wild-west vibe of a decade ago. If any of this has you seriously weighing a plant-medicine retreat for depression, addiction, trauma, or just a long-standing sense of being stuck, a range of vetted ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will wait.
Mind the Gap: How Meditation Reveals the True Nature of Thought
Sit still for ten minutes and you'll meet a stranger — the person actually living inside your head. It's rarely who you thought you were. Most first-time meditators walk away from their initial sessions a little rattled, because the running commentary they'd never really noticed before turns out to be loud, contradictory, and mostly not even interesting. That noise, and the space between the noise, is where the real work of contemplative practice begins. For readers exploring plant medicine, meditation, or any form of psychedelic healing, understanding how the mind actually behaves under observation is more than academic. It's the ground everything else stands on. The insights that arrive during a ceremony don't stick unless you have some capacity to sit with your own thinking afterward. So let's talk about what meditation actually does to the mind — starting with a slogan borrowed from the London Underground. Shamatha is often translated as calm-abiding, or sometimes just as mindfulness. Whatever you call it, the mechanic is the same: you focus attention, gently, on a chosen anchor — the breath, a sound, a candle flame — and you keep bringing it back when it wanders. Nothing dramatic. Nothing mystical. Just returning, over and over, to the present object. What happens over weeks and months of consistent practice is genuinely strange. The rushing river of thought starts to slow down. Not because you've forced it to. Because sustained attention seems to naturally decongest the mind. And then, occasionally, the whole engine stalls out for a second — and you notice a gap between one thought ending and the next one beginning. A small, quiet space. Empty. Aware. Anyone who's ridden the Tube in London knows the recorded voice at every platform: Mind the gap. It's a warning about the space between the train and the platform edge. But it works uncannily well as a meditation instruction too. Once you've felt that gap between thoughts, the practice becomes about noticing it more often, letting it widen, and resting there without grasping. That's it. That's the whole game at this stage. Here's the thing most people never question: we assume our thoughts are us. I think it, therefore I am it. This memory belongs to me, this opinion is mine, this feeling defines who I am today. It's such a total identification that we don't even see it happening. It's the water we swim in. But the moment you sit down and start watching thoughts arise — really watching them, like someone observing weather — a small crack appears in that assumption. Because if you can observe the thought, then some part of you must be separate from it. The observer and the observed can't be the same thing. That's a basic logical point that becomes an experiential one on the cushion. Why does this matter? Because when we believe our thoughts uncritically, we act on them. And a huge amount of human misery — personal and political — traces back to people being absolutely certain their thoughts are true. Ideologies are just thoughts wearing uniforms. Grudges are just thoughts we've been rehearsing for years. Even our sense of who we are, that felt story of being a particular kind of person, is a thought pattern running on repeat. Recognizing this doesn't make you cold or detached. It makes you a little freer. Almost everyone who begins meditating discovers the same uncomfortable thing in their first few weeks: their mind is chaos. Not calm, not focused, not the tidy inner landscape they'd assumed. A jumble of half-finished sentences, old resentments, random songs, low-grade worry, and running commentary on absolutely nothing. This is normal. It's not a sign you're bad at meditation. It's a sign you've started looking. The mess was always there — you just weren't paying attention. Imagine walking into a room you thought was clean and switching on a bright light. The dust was there yesterday too; now you can see it. The work is not to hate the mess or scrub it away by force. It's to observe it, get familiar with its patterns, and slowly learn which thoughts are useful and which are noise. Conceptual thinking is a beautiful tool — human intellect is what makes contemplative practice possible in the first place. The problem isn't thinking. The problem is being enslaved by thinking without realizing it. Once your attention is stable enough to sit with the mind without immediately being swept away, the practice shifts. This next phase is called vipashyana, or insight meditation. Instead of just watching thoughts flow past, you start interrogating them. The questions sound almost childish at first: You'd think the answers would come quickly. They don't. Look for a thought and it slips away. Try to pin down a feeling and it dissolves. The closer you look, the less solid everything gets. This is disorienting, in a good way. Our whole ordinary experience is built on the assumption that thoughts, emotions, and the self having them are real, solid, findable things. Investigation shows they aren't — at least not in the way we assumed. Here's where this connects to the wider world of psychedelic healing. A well-run ayahuasca or psilocybin ceremony often dissolves the felt sense of a solid, separate self, sometimes violently, sometimes with immense tenderness. People describe watching their identity fall apart and reassemble. They see through habits of thought they'd worn like armor for decades. Master plants, in the traditions that use them, are said to teach directly — often about the very illusion contemplatives spend years chasing on the cushion. But here's the honest part nobody selling retreats wants to say out loud: a psychedelic can show you something profound in a single night. Meditation is how you keep the lesson. Without some form of sitting practice — before, during dieta, and especially in the months after — the insights tend to fade back into the noise of ordinary life. Integration is basically applied vipashyana. You're using the same skills, just on richer material. People come to plant medicine for many reasons — addiction, depression, trauma, a sense of being stuck in patterns they can't name. What they usually don't realize is that the medicine works partly by showing them how much of their suffering is constructed by thought. Meditation shows the same thing, more slowly, more reliably, and without the risk of a rough night in a maloca. The two practices belong together. They're saying the same thing in different languages. There's a Tibetan image for what analysis reveals about thought. A rainbow looks vivid, arched, definitely there — until you try to walk up to it. Then it retreats. You can never actually reach it. It exists as an appearance, but nothing solid is behind the appearance. Thoughts are like that. Emotions too. Bright, convincing, seemingly real. Look closely and there's nothing to grab. The Sanskrit word for this is shunyata, usually translated as emptiness. It's one of the most misunderstood terms in Buddhist practice. Emptiness doesn't mean nothing exists. It doesn't mean nihilism, or that life is meaningless, or that you should stop caring. It means things don't exist the way they appear to — as solid, independent, immutable objects. Every thought arises out of conditions. Every emotion is shaped by what came before it. Nothing is self-contained. The mind is a stream, not a stone. Realizing this experientially — not just understanding it intellectually — changes your relationship to your own suffering. The next time an old shame surfaces, or a familiar anxiety loop starts spinning, you can watch it with a different eye. It's not you. It's weather. It's a bubble that will pop the moment you stop feeding it attention. None of this is quick. Meditation is a long practice. Plant medicine is a strong but finite experience. Both point at the same territory: the mind is not what you thought it was, and that's excellent news, because it means you're not trapped in it. Start where you are. Sit for ten minutes tomorrow. Watch your breath. When a thought arises, notice it, don't argue with it, come back to the breath. Do this for a few weeks and you'll start to feel the gap. Do it for a few months and something in you will begin to loosen. If, along the way, you feel called to explore deeper terrain — the kind of terrain that plant medicine has traditionally opened — you'll be far better prepared for it than someone who's never sat still with their own mind. For readers who want to take this further alongside a contemplative practice, a range of curated plant medicine retreats can be browsed on our marketplace here. Whatever path you choose, the instruction stays the same: mind the gap, and let the mystery reveal itself.
The Unsexy Side of Psychedelic Integration: Why Real Healing Feels Boring
Nobody posts about the Tuesday three weeks after the retreat. The one where you're standing in the kitchen at 7pm, staring at a sink full of dishes, wondering why the cosmic download you received in the maloca hasn't fixed your urge to scroll Instagram for two hours instead of calling your mother. This is the part of psychedelic integration nobody warns you about. And it's the part that actually matters. Scroll through any ayahuasca retreat's marketing and you'll find variations of the same narrative arc. Broken person arrives in the jungle. Broken person drinks the brew. Broken person weeps, purges, sees their ancestors, receives a message from the plant. Broken person emerges fixed, glowing, ready to open a wellness practice in Tulum. The problem isn't that this never happens. Sometimes something close to it does. The problem is that the story ends where the real work begins. You get the download. You come home. Then what? A lot of people I've spoken with — folks who came to ayahuasca or psilocybin for addiction, depression, or trauma — describe the ceremony itself as the easy part. Which sounds insane if you've ever spent eight hours face-down on a mat questioning whether your consciousness will ever return to your body. But they mean it. Because at least during ceremony, something is happening TO you. Integration is what you have to do yourself. Let's kill the mystique. Integration is not a special ceremony. It's not a workshop. It's not a follow-up call with a facilitator, though those help. Integration is what you do on an ordinary Wednesday when nobody is watching. Here's what it tends to look like in practice: None of that photographs well. None of it makes for a compelling retreat testimonial. But this is where the ceremony either takes root or evaporates. There's a pattern I've watched play out enough times that I think of it as the six-week cliff. For roughly six weeks after a strong plant-medicine experience, most people feel different. Lighter. More patient. Cravings quieter. Old resentments less sticky. This is real — the neurochemistry doesn't lie, and the perspective shift is genuine. Then week seven arrives. Life resumes its normal pressure. The dishes pile up. Your boss is still your boss. And whatever you didn't build a scaffolding for during those six weeks starts to slip. People who don't do the unsexy integration work often find themselves booking their next retreat within a year, chasing the state instead of doing the work the state pointed them toward. Yes. But probably not the way the brochures describe it. Real healing from addiction, trauma, or long-term depression through plant medicine tends to look less like a lightning strike and more like a very slow renovation. The medicine shows you the blueprint. It might even knock down a wall or two while you're sitting there. But you still have to do the rewiring, the plastering, the painting. Over months. Sometimes years. I've interviewed people five years out from an ibogaine treatment for heroin addiction who are still sober. When you ask them what did it, almost none of them credit the ibogaine alone. They credit ibogaine plus the therapist they found afterward, plus the 12-step meetings they resisted going to for eight months, plus the girlfriend who left them, plus the dog they had to keep alive. The medicine was the doorway. What they built on the other side was the healing. The Amazonian traditions that gave us ayahuasca have always understood this. In the vegetalista lineages, working with master plants — ayahuasca, chacruna, chiric sanango, bobinsana, and others — is a lifelong relationship, not a one-off experience. Dieta is months of restriction and isolation. The plant is understood to be a teacher, and teachers don't hand you a diploma after a single class. Something's been lost in translation as these practices moved north. We've kept the ceremony and shed the discipline around it. Which is a bit like keeping the surgery and skipping the post-operative care, then wondering why the wound reopened. If you're considering a psychedelic retreat — for addiction, for depression, for whatever brought you here — the single most useful thing I can offer is this: plan your integration before you book your ceremony. Not after. Before. Some concrete pieces to have in place: Before you book anything, ask yourself honestly: am I willing to do the boring part? Because if the answer is no — if what you want is the peak experience, the story to tell, the temporary reset — you'll get it, and it'll fade, and you'll be back where you started with a lighter bank account. If the answer is yes, though, plant medicine can be one of the most powerful catalysts available to a human being. It won't do the work for you. But it can shorten the distance between where you are and where the work needs to happen. That's not nothing. That's actually enormous. The retreat industry doesn't love this framing because it makes ceremonies sound like homework, and homework doesn't sell as well as transformation. But readers who've made it this far into an article about the unsexy side of integration are probably ready to hear it anyway. If you're seriously weighing this decision and want to see what's actually out there — the retreats that emphasise preparation and aftercare rather than just the peak — a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. Take your time with the choice. The ceremony is one night. What you build afterward is the rest of your life.
Psychedelic Conferences and Summits: Are They Worth Attending Before a Retreat?
Every year, more psychedelic conferences pop up. Denver, Amsterdam, Oakland, Miami — pick a city with a decent airport and there's probably a summit happening there sometime in 2026. The lineups look impressive on paper: neuroscientists, indigenous leaders, therapists, policy wonks, a handful of celebrity advocates who found ayahuasca and haven't shut up about it since. Tickets run anywhere from a couple hundred bucks for livestream access to several thousand for VIP packages with dinners and workshops. The question I keep getting from readers who are quietly weighing a plant medicine retreat is a fair one: do I need to go to one of these things first? Will a summit actually help me figure out whether ayahuasca is right for me, or whether I should be looking at psilocybin, or ibogaine for addiction, or something else entirely? Or is it just an expensive weekend of PowerPoints and networking cocktails? The honest answer, after having attended more of these than I can cleanly remember, is: sometimes yes, often no, and it depends heavily on where you are in your process. Let me walk you through what these events actually deliver, what they don't, and whether the ticket price makes sense for someone whose real goal is deciding on a retreat. A psychedelic conference is essentially a professional gathering with a public-facing wrapper. The core audience is researchers, clinicians, facilitators, lawyers working on legalization, and entrepreneurs building the psychedelics industry. Around that core, organizers layer in tracks for curious civilians — the retreat-curious, the microdose-curious, the trauma-survivor who read a book and wants to know more. You'll sit through panels on things like the current state of MDMA-assisted therapy trials, the ethics of extracting ayahuasca knowledge from the Amazon, ketamine clinic business models, and whether psilocybin should be regulated like alcohol or like therapy. Some of it is genuinely fascinating. Some of it feels like watching people argue about which shade of beige to paint a room you've never been in. What a summit is not: a retreat, a ceremony, or in most cases even a place where any actual plant medicine is legally consumed. You will not drink ayahuasca at a Denver conference. You will drink expensive kombucha and talk about ayahuasca. There's a difference, and it's the difference that matters most for a reader trying to decide about their own healing. There are real reasons someone considering plant medicine might benefit from attending a summit first. Let me lay them out honestly. First, information density. In three days you can hear from twenty or thirty people who've spent decades on this material — indigenous elders, harm reduction workers, integration therapists, researchers running trials at Johns Hopkins or Imperial College. That kind of concentrated exposure would take months to piece together from podcasts and articles. If you're the type who learns by absorbing lots of perspectives at once, a good conference does compress the learning curve. Second, the vetting factor. Retreat facilitators sometimes exhibit at these events, or speak on panels, or hang around the hallways. You get to see how they carry themselves in a professional setting, what questions they can answer under pressure, whether their claims hold up when a scientist in the front row asks a follow-up. Some of the most useful conversations I've had about specific retreats happened over conference-hotel coffee, not on a website. Third, you meet other people in your shoes. Not the peacocking types — the quieter ones, standing near the back, who've also been thinking about this for two years and haven't told their family. Those conversations are worth the ticket alone sometimes. Here's where I'll be blunt. The psychedelic conference circuit has developed a particular flavor over the past few years, and it isn't always in service of the retreat-seeker. A lot of the programming is aimed at investors and industry insiders. Which sessions are running in the biggest ballroom? Often the ones about drug patents, clinic scaling, insurance reimbursement, and stock performance of the handful of publicly traded psychedelic companies. Fascinating for a certain audience. Almost entirely irrelevant to someone trying to figure out whether to book a two-week ayahuasca retreat in the Sacred Valley. There's also the hype problem. Summits tend to attract voices that oversell. You'll hear speakers describe psychedelics with a certainty that anyone who's actually sat in enough ceremonies knows is unwarranted. Master plants don't work on everyone. Ayahuasca doesn't heal every trauma. Ibogaine isn't a magic bullet for opioid addiction, though for some people it's remarkable. If you walk into a conference thinking these medicines might help you, and walk out convinced they definitely will, you've been mis-sold something important. And the money. A three-day pass to a major summit can cost the same as a mid-range week-long retreat. If your budget is finite — and for most people it is — spending it on the actual work of sitting with the medicine will almost always outperform spending it on watching other people talk about the medicine. Based on where the field is heading right now, the major themes at this year's summits are pretty predictable. Expect a lot of oxygen given to the FDA's continued deliberations on MDMA and psilocybin, the rollout of Oregon and Colorado's regulated psilocybin programs, and the growing conversation about ibogaine as veterans and addiction-recovery communities push for research funding. There'll be sessions on indigenous reciprocity — the ethical question of what the global demand for ayahuasca owes to the Amazonian communities whose ancestors developed this tradition. This is worth listening to, especially if you're planning to travel to Peru, Brazil, or Ecuador. The way you spend your retreat dollars matters, and reputable retreat centers are increasingly transparent about how they support their host communities. Expect also the recurring debate about whether psychedelic healing should live inside the medical system, the traditional-ceremony framework, or some hybrid. Nobody has a clean answer. That messy conversation is actually more useful than the confident sales pitches, because it prepares you for the reality that plant medicine work doesn't fit neatly into any single container. If I had to advise a friend who was seriously considering ayahuasca for depression, or psilocybin for grief, or an ibogaine program for opioid dependence, I probably wouldn't tell them to buy a summit ticket first. Not because summits are worthless — they're not — but because there are cheaper, denser ways to get most of the same information. Read three or four honest books. Listen to a couple dozen carefully chosen podcast episodes, especially the ones with facilitators and integration specialists rather than podcast celebrities. Get on a call with two or three retreat centers and ask them the hard questions — screening protocols, medical staff on-site, what happens if someone has a psychiatric emergency, how they handle sexual safety, what integration support they offer after you fly home. Talk to people who've done a retreat you're considering. Those conversations will tell you more than any keynote. Then, if after all that you still feel you'd benefit from being in a room with a thousand other people wrestling with the same questions, go to the summit. But go with your priorities sorted, not to figure them out. That last question is the tell. If you can name one specific reason — a facilitator you're vetting, a researcher whose work bears directly on your situation, a workshop on integration you've been unable to find elsewhere — the ticket is probably worth it. If you can't, the summit is probably a very expensive way to procrastinate on the decision you already know you need to make. Here's what I've noticed after years of talking to people at these events. The ones who go to a summit and then book a retreat within a few months usually would've booked the retreat anyway — the conference just gave them permission to stop researching and start doing. The ones who go to summit after summit without ever actually sitting with the medicine are almost always avoiding something. Usually fear, sometimes something more tender than fear. Neither of those is wrong. But it's worth being honest with yourself about which one you are. Plant medicine work asks you to stop consuming information about your suffering and start facing it. At some point, the research phase has to end. If you're closer to that point than you'd like to admit, and the summit ticket is really a way to buy another six months of thinking about it, consider skipping the conference. For readers ready to look at what's actually available, a range of curated ayahuasca and plant medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it with clear eyes.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Treating Depression with Psilocybin Truffles: What a Second Journey Can Reveal
There's a particular kind of quiet that settles into a room after someone's second psilocybin session ends. Different from the first. The first trip is mostly astonishment — the walls breathing, the ego dissolving, the sudden conviction that everything is going to be different now. The second one? That's where the actual work tends to begin. And for people using truffles to treat depression, that second journey is often the one that matters most. I've spent enough time around plant-medicine and psychedelic retreats — sitting in on ceremonies, talking to facilitators in the Netherlands where truffles remain legal, following up with participants months later — to notice a pattern. People come in hoping psychedelics will fix them. What actually happens is stranger, slower, and more useful than that. Truffles — the sclerotia of certain psilocybin-producing fungi — occupy an odd legal niche. In the Netherlands they're sold openly, which is why most of the legitimate psilocybin retreats you'll find operate out of places like Amsterdam, Utrecht, or the Dutch countryside. The active compound is the same one that's been studied at Johns Hopkins, Imperial College London, and NYU for treatment-resistant depression. Clinical trials over the past several years have shown response rates that outperform SSRIs for a meaningful subset of participants, particularly those who've cycled through multiple medications with diminishing returns. That research is why people are showing up at retreats now who wouldn't have considered it a decade ago. Software engineers on their third antidepressant. Nurses who've been quietly depressed since their twenties. Parents whose depression hardened after a loss. The demographic has shifted from psychonauts to patients — and the framing has shifted with it. Still, psilocybin isn't a pill you swap in for citalopram. It's a full-day event, sometimes two, with preparation before and integration after. And what happens inside that day tends to divide neatly into two kinds of experience: the opening, and the excavation. Most people's first truffle session is the beautiful one. The dose is usually moderate — maybe 15 to 25 grams of fresh truffles depending on the facilitator's protocol and the participant's weight and sensitivity. You lie down with an eye mask, headphones playing a curated music set, and a sitter or two nearby. Within forty minutes, the world softens. What people report from a first session tends to cluster around a few themes: This is the trip people write about. It's the one that gets Instagrammed (metaphorically — good retreats don't allow phones in the ceremony space). And it's genuine. The neuroplasticity spike, the default mode network quieting, the flood of connection — all of it is real. But here's what almost no one tells you about a first psilocybin session for depression: the afterglow fades. Sometimes within days, sometimes within a few weeks. And when it does, some people crash harder than before, because they thought they were done. The second session tends to feel different from the moment the truffles hit. Less carnival, more clinic. People describe it as heavier, more surgical, sometimes uncomfortable in ways the first one wasn't. This isn't a failure of the medicine — it's usually the medicine doing what depression treatment actually requires. In depression, the material that needs to surface is rarely pleasant. It's the memory of being seven years old and realizing no one was coming. It's the resentment toward a partner you've been swallowing for a decade. It's the grief you never let yourself feel because you were too busy functioning. A second psilocybin trip tends to open those specific rooms — the ones the first trip only walked past. Facilitators who've sat with hundreds of sessions will often tell you the second journey is when they see people actually change, not just feel changed. There's a difference. The first trip generates insight. The second one forces you to sit with what the insight implies. Which is usually harder. If you're considering a truffle retreat and you've read glowing accounts of first-timers, prepare yourself for the possibility that your second session — if there is one — might not match that tone. That's not a warning to scare you off. It's the opposite. Knowing this in advance is what lets you stay with the experience instead of fighting it. A few things worth knowing: Not every truffle retreat is equipped for people using the medicine to treat mental illness. Some are geared toward well-adjusted seekers looking for spiritual experience. That's a different program. If depression is your reason for going, look for a few specific things: Ask about the screening process. A retreat that takes a fifteen-minute intake call and clears you is not paying attention. Serious operators want to know your medication history, your family psychiatric history, whether you're actively suicidal, whether you have bipolar disorder or a personal or family history of psychosis. If they don't ask, that's a red flag. Ask about the facilitator-to-participant ratio. Anything worse than one facilitator per four participants is thin. Ideally you want closer to one-to-two or one-to-three, with at least one facilitator who has clinical training in addition to psychedelic experience. Ask what happens if your session gets hard. The answer should involve specific practices — physical presence, grounding techniques, permission to feel what's arising — not vague reassurance. And ask what integration looks like: how many sessions, over how many weeks, with whom. Finally, trust your instincts about the operators themselves. Depression makes people vulnerable to charismatic figures promising transformation. A good facilitator will be honest about what psilocybin can and can't do, will not promise you'll be "healed," and will treat you as a competent adult making a serious choice — not as a lost soul who needs saving. People who use psilocybin truffles to treat depression and get lasting results tend to share a few habits. They don't treat the retreat as a one-and-done. They keep working — with a therapist, ideally one who understands psychedelic integration, and often with lifestyle changes that would have felt impossible before the sessions. They stay in touch with the insights that surfaced, even the uncomfortable ones. They accept that depression, for many people, is a chronic condition being managed rather than a bug being patched. The second trip that felt heavier than the first? For most people who follow through, that's the one they end up grateful for. Not because it was pleasant, but because it was honest. If you're weighing this decision and want to see what's actually out there, a range of legal psilocybin truffle retreats can be browsed on our marketplace here. Take your time with the choice — the retreat you pick matters at least as much as the medicine itself.
When the Mind Won't Quiet: What Plant Medicine Teaches About Stillness
Three in the morning. You're staring at the ceiling again, running the same tape — the argument from last Tuesday, the email you didn't send, the thing your mother said in 2011. Somewhere in that loop, a quieter voice suggests you look into an ayahuasca retreat. Not because you've become the sort of person who does that. Because nothing else has worked. This is how most people I've met on the psychedelics path actually arrive. Not through a spiritual awakening at a music festival. Through exhaustion. Through years of talk therapy that helped a little, SSRIs that flattened them out, meditation apps abandoned by week three. The pitch of plant medicine — ayahuasca, psilocybin, ibogaine, the whole master plants family — isn't that it's magic. It's that it works on something the other tools can't quite reach. Ten years ago, if you told your GP you were considering an ayahuasca ceremony for your drinking problem, they'd have suggested a psych evaluation. Today, half of them have read the same Johns Hopkins studies you have. Psilocybin trials for treatment-resistant depression. Ibogaine research on opioid dependence. The 2006 Supreme Court ruling that carved out a religious exemption for the UDV to use ayahuasca legally in the United States. The ground has shifted. What the researchers are circling around — and what indigenous traditions have said for centuries — is that certain compounds seem to loosen the grip of entrenched patterns. Addiction. Depression. The stories we tell ourselves about who we are and what we deserve. The clinical language calls this neuroplasticity. The Shipibo would call it a conversation with the plant. Both framings point at the same thing: something in the psychedelic experience makes the mind briefly negotiable. And for people who have spent decades unable to negotiate with themselves, that window matters. I want to be honest about this part, because retreat marketing tends to skip it. A traditional ayahuasca ceremony is not comfortable. You drink a bitter brew that tastes like something scraped from the floor of a garage. You wait. Sometimes you throw up — and in the tradition, the purge is considered part of the medicine, not a side effect. Then, usually, the visions come. Sometimes gentle. Sometimes not. People describe watching their own biography from the outside. Meeting versions of themselves at seven, at fifteen, at the age they first started drinking. Some describe encounters with what they can only call the plant's intelligence — a felt presence that seems to know things about them they'd never spoken aloud. Whether you interpret that as a real entity, a projection of the unconscious, or the DMT receptor doing something strange, the experience is the same: you can't argue with it. Psilocybin retreats — increasingly common in the Netherlands, Jamaica, and now parts of the U.S. where local decriminalisation has opened space — tend to feel gentler. Less physical purge, more emotional unspooling. San Pedro (huachuma) ceremonies in the Andes run longer and warmer, often outdoors in daylight, with a quality participants describe as grandfatherly. Ibogaine is its own beast entirely — a long, hard, sometimes 24-hour experience mostly used in clinical settings for opioid interruption. The honest range in 2026 looks something like this: If you see something significantly cheaper, ask what's missing. If you see something dramatically more expensive without clinical justification, ask what you're paying for. There's a whole category of luxury psychedelic retreats now that charge boutique-hotel prices for what is essentially a ceremony plus a nice smoothie bar. Not necessarily worse, not necessarily better — just understand what you're buying. The plant medicine world has grown fast, and not everyone selling ceremonies should be. Some things I've learned to watch for: People sometimes ask which plant medicine is right for them, as if there's a flowchart. There isn't, exactly. But there are tendencies. Ayahuasca tends to work on people carrying complex trauma, generational patterns, and the sort of grief that lives in the body. It's confrontational. It shows you things. Most people find it harder than they expected and more useful than they'd hoped. Psilocybin, in retreat contexts, seems to sit better with depression and anxiety. The experience is more mutable, easier to shape with music and setting. The clinical trials showing sustained improvement in treatment-resistant depression have used psilocybin, not ayahuasca, which is why it's the compound moving fastest through regulatory approval. Ibogaine is the specialist tool. It's used almost exclusively for interrupting opioid, methamphetamine, or heavy alcohol dependence. It's not something you take for personal growth. It carries real cardiac risks and requires medical supervision. But for people who've cycled through detox programmes and relapsed repeatedly, it's sometimes the thing that finally breaks the loop. San Pedro and peyote work differently again — slower, longer, more open. People often go to these when they want the medicine without the intensity of an ayahuasca night. Here's the thing retreat brochures don't say enough. You will come home from a ceremony feeling either euphoric, disoriented, cracked open, or all three at once. The insights will feel obvious and permanent. Then Tuesday will happen, and your inbox, and the person you live with, and by Friday you'll be wondering if any of it was real. Integration is what makes the difference between a psychedelic retreat that changes your life and one that becomes an interesting story you tell at dinner parties. It looks like: journalling, therapy with someone who understands psychedelic experiences, changing what you eat and who you spend time with, actually sitting with the uncomfortable stuff the medicine showed you rather than filing it away. It takes months. Sometimes years. People who do the integration work tend to keep the gains. People who don't, don't. It's genuinely that simple, and genuinely that hard. I can't answer that. Nobody can, honestly, except you, and even you probably can't answer it fully until you've done it. But there are signs it might be worth exploring: If any of that resonates, the next step isn't booking. It's reading, talking to people who've done it, and being honest with yourself about what you're hoping to find. For readers who want to keep researching, a curated selection of ayahuasca, psilocybin, and other plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The plants, whichever ones you end up meeting, aren't going anywhere.
Watching Thoughts Is Easy — Watching Yourself Watch Them Is the Real Work
There's a stage in meditation — and, honestly, in the deeper end of plant medicine work — where people get very good at watching their thoughts. They sit down, close their eyes, and observe the mental weather rolling through. A worry about rent. A snippet of a song. A flash of that awkward thing they said in 2019. They label it, let it drift, come back to the breath. Easy. Kind of satisfying, even. Then somebody — a teacher, a facilitator, an ayahuasca ceremony that cracks you open at 2 a.m. — asks the harder question. Who is watching? And can you notice that one too? That's when things get interesting. And uncomfortable. Because the second layer of awareness — noticing the noticer — is where the real practice lives, and it's the exact skill that separates a pleasant meditation habit from a genuine shift in how you move through your life. Most of us, when we first learn to meditate, are taught some version of the same instruction. Sit. Breathe. Watch what comes up without grabbing it. Thoughts are clouds, you are the sky — that sort of framing. It's a good instruction. It works. Within a few weeks of consistent practice, most people can genuinely observe their thoughts without immediately being swallowed by them. This alone is life-changing for a lot of folks. The person who used to spiral for hours over one critical email now catches the spiral at minute three and steps out of it. That's not nothing. For anyone working through anxiety, depression, or the low-grade static of modern life, that gap between stimulus and reaction is where freedom lives. But here's the catch nobody tells you at the beginner retreat: watching thoughts, once you get halfway decent at it, becomes another thing the ego does. You're still doing meditation. There's still a subtle sense of a controller sitting behind your eyes, congratulating itself for staying calm. That controller is the thing you eventually need to see through. Try this now, if you want. Notice a thought — any thought. Now notice the noticing. Notice who's aware of the awareness. Most people, doing this for the first time, hit a kind of soft wall. The mind wobbles. You either land in a quiet, wordless open space for a second — or the ego panics and generates another thought to observe, because at least that feels like something to hold onto. This is the doorway. It's also the reason experienced meditators talk about their practice going in cycles: you get comfortable at one layer, and then the floor drops out and you're back to being a beginner, only in a subtler room. Contemplative traditions have been mapping this for a long time. In Dzogchen they call it rigpa — the awareness that's aware of itself. Advaita teachers point at it with the phrase “I am.” Zen has koans designed specifically to short-circuit the watcher-watching-thoughts loop and force a direct encounter with what's underneath. Different maps, same territory. Here's where things get relevant for anyone reading this while quietly researching an ayahuasca retreat or a psilocybin ceremony. Master plants like ayahuasca, psilocybin, and San Pedro have a way of dismantling the observer very efficiently. Sometimes brutally. What takes ten years of committed sitting practice can get vaporized in a single night, at least temporarily. In a strong ayahuasca ceremony, the sense of “I am watching my experience” frequently dissolves. There's still experience — vivid, sometimes overwhelming experience — but the tidy watcher behind it evaporates. People describe this as terrifying, liberating, or both at once. It's why integration matters so much. Without a framework for what just happened, the mind will usually rush back in and try to file the whole thing away as either “a profound spiritual experience” or “what was I even thinking” — both of which are just the ego re-establishing itself as the one in charge. This is one reason plant medicine and contemplative practice pair so well. Meditation gives you the vocabulary and the nervous-system stability to hold what psychedelics show you. Psychedelics show you, in a few hours, what meditation is patiently pointing toward. Neither alone is quite enough for most people. The reason this matters isn't philosophical. It's practical. Most of what makes life hard — addiction patterns, reactive anger, chronic anxiety, the sticky loops of trauma — runs on an unquestioned sense of a “me” who has to defend itself. Loosen the grip on that watcher, even a little, and behavior starts to change on its own. Not because you decided to change it. Because the thing that was driving the behavior isn't as solid as it seemed. People coming out of a well-held plant medicine retreat often report this exact phenomenon. The craving is still there sometimes, but the compulsive quality has softened. The old argument with a parent replays in the mind, but nobody rushes to grab it. The identity around “I'm the kind of person who…” becomes negotiable. None of this means the second-layer awareness is some enlightened trophy to collect. It's more like a muscle you can develop, lose, and rediscover throughout a lifetime. A few things tend to go sideways once people start playing with second-layer awareness. The first is intellectualizing. You read enough books about nondual awareness and you start thinking about the witness instead of resting as it. The mind is very good at turning any insight into a new concept to collect. If your practice is generating a lot of interesting ideas and not much lived quiet, you're probably in this trap. The second is spiritual bypassing. “There's no self, so my trauma isn't real, so I don't need to deal with it.” This is a disaster, and it's especially common in people who've had a big psychedelic experience and mistake the taste of dissolution for full liberation. The nervous system still holds what it holds. The body still needs to be met. Awareness practice complements therapy and somatic work; it doesn't replace them. The third — and this one is quieter — is grasping. Once you've had a glimpse of that spacious, watcher-less quality, you'll want it back. You'll sit down expecting it. You'll be disappointed when your meditation is just a regular meditation. The wanting itself becomes the wall. Which is, of course, another thing you can notice. You don't need a retreat to do any of this. A steady daily practice, a decent teacher, and honest self-inquiry will get you there over time. But there's a reason people still go on retreat — silent meditation retreats, ayahuasca retreats, psilocybin retreats. Concentrated time, held container, no laundry to do. The layers of awareness open faster when nothing is pulling you back to the surface. If you're considering a plant medicine retreat specifically for this kind of inner work, look for facilitators who talk about integration as much as they talk about ceremony, who have some grounding in contemplative practice themselves, and who don't promise you enlightenment in a weekend. Red flag any place that does. For readers who want to take this further, a range of curated ayahuasca and psychedelic retreats can be browsed on our marketplace here. The invitation, whether you sit on a cushion tomorrow morning or fly to the Amazon next spring, is the same. Watch your thoughts. Then, gently, see if you can catch the one who's watching. That's where the practice actually begins.
When Ayahuasca Goes Wrong: Psychosis, Mental Health Screening, and the Risks Nobody Advertises
Somewhere on the internet right now, a person is typing a story into a forum thread. It goes something like this: they went to an ayahuasca retreat hoping to heal, and instead they came home hearing voices. Or unable to sleep for weeks. Or convinced, with a clarity that terrifies their family, that something followed them out of the jungle. These stories exist. Not many, relative to the number of people who sit in ceremony each year — but enough that anyone considering a psychedelic retreat deserves an honest conversation about them. Most retreat websites won't have that conversation with you. So let's have it here. Ayahuasca has become the poster child for plant-medicine healing. You've seen the language — trauma dissolved, addictions lifted, depression walked off like a heavy coat. A lot of that is real. Clinical trials, observational studies, and countless first-person accounts point to genuine therapeutic value, particularly for people stuck in patterns that talk therapy alone hasn't shifted. But ayahuasca is not a wellness smoothie. It's a powerful psychoactive brew containing DMT and MAO inhibitors, taken in a setting designed to crack you open. For most participants, that crack becomes an opening. For a small minority — and this is the part the glossy retreat sites tend to hide behind fine print — it becomes a fracture that takes months or years to close, if it closes at all. The most serious of those adverse outcomes is psychosis. And the people most at risk of it are often the same people most drawn to plant medicine in the first place: those carrying heavy trauma, family histories of mental illness, or a quiet suspicion that something in their psyche is already fragile. Psychiatric literature on this is thin but growing. The pattern, when it appears, tends to unfold in one of two ways. The first is an acute episode during or immediately after the ceremony — someone becomes disoriented, terrified, unable to distinguish the visionary state from consensus reality, and doesn't come back down when the pharmacology should have worn off. The second is a delayed onset, sometimes weeks after returning home, where symptoms creep in: intrusive voices, paranoid thoughts, ideas of reference, sleep collapse, a growing certainty that spirits or entities are still present and interactive. People who've been through it often describe the second kind as harder to name. You've had a profound ceremony. You expect to feel changed. When the changes start to feel less like insight and more like intrusion, it's easy to explain them away — that's just the download, that's just my ego resisting, that's just an entity attachment I need to work with. Meanwhile, actual clinical symptoms are consolidating. Family members are often the first to notice. If someone you love comes back from a retreat and their behavior scares you, trust that instinct. Early intervention matters. Psychiatric care in these situations is not a betrayal of the medicine — it's the responsible next step. No screening system catches everyone. But there are patterns in the case reports and in what experienced facilitators quietly acknowledge. If any of the following describe you, ayahuasca deserves a much longer conversation with a medical professional than the online intake form provides. None of these are automatic disqualifiers in every case. But they should stop the booking process cold until you've talked with a psychiatrist who understands psychedelics — not a facilitator whose income depends on you saying yes. The difference between a solid retreat and a dangerous one is usually visible in the intake process before you ever board a plane. A trustworthy operation will ask uncomfortable, specific questions about your psychiatric history, your medications, your family history, and your reasons for coming. They'll want a phone or video call, not just a form. They'll say no to some people, and they'll tell you why. The red flags run in the other direction. A retreat that never asks about mental health history. A facilitator who tells you the medicine will “know what you need” and dismisses your concerns about a family history of schizophrenia. A place that offers to hold ceremony for anyone with the money to attend, regardless of what they disclose. A brochure that promises specific outcomes — depression cured, PTSD healed — as if the plant were a prescription drug with a guaranteed mechanism. Ask direct questions before you book: If those questions annoy the person on the other end, you have your answer. Even when the ceremonies themselves go well, the weeks after are where trouble tends to consolidate or resolve. Retreats that hand you an incredible experience and then wave goodbye at the airport are doing half the job. Integration — the ongoing work of making sense of what happened and weaving it back into ordinary life — is where genuine healing lives, and it's also where early warning signs of a bad outcome first appear. A good integration setup includes structured group calls in the weeks after the retreat, access to a facilitator or integration coach who can distinguish spiritual emergence from clinical crisis, and a clear referral pathway to a psychedelic-informed therapist if things start heading somewhere concerning. Ask about all of that before you pay a deposit. And build your own support scaffold too. Line up a therapist at home before you leave. Tell one trusted person your full itinerary and what you're doing. Plan a landing week where you don't jump straight back into work. These are unglamorous logistics, and they are worth more than any additional ceremony night. None of this is meant to scare anyone away from plant medicine. The genuine potential of ayahuasca — for addiction recovery, for depression that hasn't budged, for grief and trauma that have calcified — is real, and for a lot of people it's the most significant experience of their adult lives. Master plants have earned their reputation across centuries for good reason. The point is that psychedelic healing carries actual risk, and the risk isn't distributed evenly. Some people should walk toward the medicine. Some should walk carefully. Some should walk the other way, at least for now, and revisit the question when their mental health foundations are steadier. Only you and a good clinician can tell which one is you — a retreat's marketing copy can't. If you've done the honest work, cleared the screening, and feel ready, a wide range of carefully vetted ayahuasca retreats can be browsed on our marketplace here. Take the extra week to ask the hard questions before you book. The retreat that answers them well is the one worth attending.
Weed, Moderation, and Meditation: An Honest Look at Cannabis and the Inner Path
Somewhere around the third week of a daily sitting practice, most cannabis users start to notice something odd. The joint before bed doesn't feel like it used to. The morning meditation feels murky the day after. Or — and this is the one nobody talks about — the practice itself starts pulling harder than the weed does, and that's uncomfortable in a way you didn't expect. This is one of those topics that gets flattened into two camps online. One side treats cannabis as a sacred plant ally, full stop. The other treats it as a moral failing that will torpedo your practice, full stop. Neither is honest. If you're the kind of person who has landed on an article like this, you probably already know the truth is messier — and more interesting — than either extreme. A lot of people find meditation through the same door they found cannabis: they were looking for relief. Anxiety, insomnia, a mind that won't shut up, grief that won't move. Weed took the edge off. Then at some point it stopped working, or started to cost more than it gave, and meditation showed up as the next thing to try. What happens next is where it gets interesting. Some people quit cannabis cold the day they start sitting. Some keep smoking daily and never notice a conflict. Most land somewhere in between, wondering whether their nightly bowl is undermining what they're building on the cushion — or whether that's just guilt talking. The honest answer, from my own years around meditation halls and ceremony spaces, is that it depends. But it depends on specific things, and those things are worth naming. Let's get concrete. Meditation, at its root, is about clearly seeing what is happening in your mind and body. That's it. Concentration, insight, equanimity — all of it downstream of that one skill. Cannabis alters perception. That's the whole point of using it. So the question isn't whether it changes your inner landscape (it does), but whether that change helps or hinders the specific thing meditation is trying to build. A few patterns I've seen consistently: None of this means cannabis is incompatible with contemplative life. It means the relationship needs honesty. There's a certain flavor of advice online that says any use is too much use. I don't buy it, and I've watched too many thoughtful people integrate occasional cannabis into a serious practice to pretend otherwise. But moderation has to actually mean something. Here's what I've watched work for people: Moderation, in practice, tends to mean cannabis becomes something occasional and specific — a Friday night, a social evening, a walk in the woods — rather than a nightly ritual you barely notice performing. This is where things get interesting for readers who've been circling the idea of a psychedelic or ayahuasca retreat. Cannabis is a plant medicine, technically. But it functions very differently from the master plants — ayahuasca, psilocybin, iboga, San Pedro — that people travel to sit with. The master plants tend to demand something of you. Preparation. Dieta. A period of abstinence beforehand — and most reputable ayahuasca retreats will ask you to stop cannabis use for at least two weeks (often longer) before you arrive. There are reasons for this that go beyond ceremony etiquette. The plants seem to work more cleanly in a nervous system that hasn't been steeped in daily THC. Facilitators who've watched thousands of ceremonies will tell you the same thing, quietly, if you ask. Some traditions consider cannabis itself a teacher plant when used ceremonially, particularly in certain Indian and Rastafarian contexts. That's real, and it's not what most Western daily use looks like. A bhang-drinking sadhu on the banks of the Ganges is doing something structurally different from someone hitting a vape pen on the couch after work. Both may involve the same molecule. The relationship is not the same. Cannabis use disorder is real. The idea that weed isn't addictive was cultural cope from the 1990s that hasn't survived contact with the current market, where THC concentrations have climbed dramatically and daily use has become mainstream. If you've tried to stop and couldn't, or tried to cut back and didn't, or find yourself defending your use with more energy than the topic deserves — that's worth looking at. For some people, meditation is enough of a lever to shift the relationship on its own. Sitting with discomfort daily builds a tolerance for not-reaching-for-the-thing that generalizes surprisingly well. For others, meditation reveals the depth of the habit without providing the exit, and that's when people start looking at more intensive options — retreats, therapy, sometimes plant-medicine work aimed specifically at breaking patterns. Ibogaine and ayahuasca have both shown promise for people trying to unstick from various substances, cannabis included. The evidence base is still forming, but the anecdotal reports from people who've done the work honestly are hard to dismiss. A well-run retreat isn't a magic bullet — the integration afterward is where the actual change happens — but it can crack open something that ordinary willpower can't. If you're reading this because you're wondering whether your relationship with cannabis is helping or hurting your inner work, here's what I'd suggest before you make any big decisions: For readers who suspect their cannabis use is more entangled than they'd like — with anxiety, with sleep, with trauma, with just the general low-grade static of modern life — a retreat setting can offer something ordinary life can't. Time away from your triggers. Skilled facilitators. A container designed for exactly this kind of work. Not every retreat is the right retreat, and not every person is ready for one. Do the reading, ask hard questions, talk to people who've been. If you're drawn specifically to plant-medicine work as part of unwinding a stuck relationship with cannabis or anything else, a range of ceremonies and healing-focused retreats can be browsed on our marketplace here. The cushion is still the cheapest, most portable, and most reliable technology humans have ever developed for meeting themselves honestly. Weed is a tool with real costs and real uses. The work is figuring out which is which, in your life, right now. Nobody else can do that for you — and that, oddly, is the good news.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
